Study Looks at Effect of High Blood Fats in MS Patients

The purpose of the study, which was published in the Journal of Vascular Research, was to determine the effect of a person’s blood lipids on the major arteries outside the skull.

In addition to previous work that demonstrated associations between hyperlipidemia — which is an abnormally high concentration of fats or lipids in the blood — and worse clinical and radiological outcomes in people with MS, this study shows a link between hyperlipidemia and greater problems with the extracranial arteries.

“This study provides another research avenue that may supplement previous findings published by our comprehensive MS group, including hyperlipidemia effects on disability progression, greater brain lesion formation and greater brain atrophy,” says Dejan Jakimovski, MD, a student in the doctoral program in neuroscience in the Jacobs School of Medicine and Biomedical Sciences, who was the lead author of the study.

MS is an unpredictable, chronic illness involving the central nervous system. In MS, the immune system attacks the myelin, which is the protective layer around nerve fibers. This causes inflammation and scar tissue, or lesions. This can disrupt the flow of information with the brain, and between the brain and body.

Research has presented increasing evidence that environmental factors can influence MS occurrence and progression. The presence of cardiovascular diseases and cardiovascular risk factors has been recently highlighted as an important driver of MS occurrence and greater disease progression within the aging MS population.

The symptoms of MS vary and can change over time. 

Common symptoms include:

• fatigue
• numbness or tingling
• weakness
• dizziness and vertigo
• pain and itching
• walking difficulties
• stiffness and spasms
• vision problems
• bladder and bowel problems
• cognitive changes
• depression

Less common symptoms include speech problems, tremors, breathing problems, swallowing problems, seizures and hearing loss.

During the study, researchers used non-contrast magnetic resonance angiography (MRA), a type of MRI that looks specifically at the body’s blood vessels.

MRA is used to generate images of arteries in order to evaluate them for stenosis, or narrowing; occlusions, or blockage; aneurysms, an excessive enlargement of an artery caused by a weakening of the artery walls; or other abnormalities.

The researchers performed MRAs on 104 people with MS and 41 healthy control subjects.

The cross-sectional area of the common carotid artery and vertebral artery (the two major arteries in the neck) was measured using a semi-automated edge-detection/contouring method at the C4-C7 vertebrae in the subjects’ cervical spines.

The lipid profile was obtained at the time of the scan. Repeated measures analyses that adjusted for age, gender and body mass index were used.

After the MRAs were completed, researchers found a significant association with a moderate effect of age on the size of the arteries in people with MS.

They also found that lipoprotein (a) — a highly atherosclerotic lipid — had a strong effect on the vertebral arteries. These associations were not present in healthy control subjects.

Those people with MS who were in the highest lipoprotein (a) quartile had significantly larger common carotid and vertebral arteries when compared to those with lower lipoprotein threshold values.

Although the clinical and pathological significance of these associations remains unknown, “the effect of lipoprotein (a) on the extracranial arterial vasculature is potentially another mechanism of action by which lipids and hyperlipidemia may interact with the complex MS pathophysiology,” Jakimovski says.

Co-authors in the Jacobs School are:

• Richard W. Browne, PhD, professor of biotechnical and clinical laboratory sciences
• Bianca Weinstock-Guttman, MD, professor of neurology and director of the Jacobs Multiple Sclerosis Center for Treatment and Research at UBMD Neurology
• Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center (BNAC)

Murali Ramanathan, PhD, professor of pharmaceutical sciences in UB’s School of Pharmacy and Pharmaceutical Sciences, is also a co-author.

Laura Pelizzari, PhD, of IRCCS Fondazione Don Carlo Gnocchi in Milan, Italy, is also a co-author.

The study was conducted on MS patients who were recruited between 2015 and 2018 at the BNAC.

These patients were part of a larger prospective study that looked at the role of cardiovascular, environmental and genetic risk factors in MS patients. As part of that study, additional work on cardiovascular health in MS patients has been published in the European Journal of Neurology and the Journal of Neurology.

The study was funded in part by the Annette Funicello Research Fund for Neurological Diseases, the Jacquemin Family Foundation, the National Center for Advancing Translational Sciences of the National Institutes of Health and internal resources of the BNAC.